Zylin D 50/20 Capsule DR contains Pregabalin 50 mg and Duloxetine 20 mg, formulated as a delayed-release capsule indicated for the management of neuropathic pain, generalized anxiety disorder, and major depressive disorder. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels in the central nervous system, thereby reducing the release of neurotransmitters involved in pain and seizure activity. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant and analgesic effects. The combination of these two agents provides synergistic efficacy in alleviating neuropathic pain and improving mood disorders by targeting multiple pathways. Zylin D 50/20 Capsule DR is typically prescribed when monotherapy is insufficient or when both neuropathic pain and depressive symptoms coexist. The delayed-release formulation ensures optimal absorption and sustained therapeutic plasma concentrations, minimizing gastrointestinal side effects. Dosage should be individualized based on patient response and tolerability, with careful monitoring for adverse effects such as dizziness, somnolence, dry mouth, nausea, and potential serotonin syndrome. Caution is advised in patients with hepatic or renal impairment, and abrupt discontinuation should be avoided to prevent withdrawal symptoms. This combination therapy should be used under strict medical supervision to ensure safety and efficacy.